Virpax Pharmaceuticals Company Overview
About Virpax Pharmaceuticals
Virpax Pharmaceuticals (NASDAQ:VRPX) specializes in developing innovative pharmaceutical solutions aimed at improving patient outcomes in pain management and other critical therapeutic areas. The company focuses on creating and advancing a diverse portfolio of product candidates using proprietary delivery technologies designed to enhance patients' lives while addressing the limitations of current treatments. Their projects span a range of formulations and delivery methods, including non-opioid pain management options and therapies for central nervous system disorders, reflecting their commitment to tackling some of the most pressing healthcare challenges. With a goal to revolutionize pain management and ensure better therapeutic efficacy, Virpax Pharmaceuticals is dedicated to pushing the boundaries of science to find new ways to serve patients and the medical community.
Snapshot
Operations
Products and/or services of Virpax Pharmaceuticals
- Envelta™, an opioid-free pain management product aiming to address severe pain with a non-addictive formulation.
- Probudur™, a long-acting liposomal bupivacaine formulation designed for post-operative pain relief.
- Epoladerm™, a diclofenac epolamine spray film for acute pain, offering targeted, non-opioid pain management.
- AnQlar™, an antiviral nasal spray for the prevention of viral replication in nasal passages.
- OSF200, a cannabidiol-based product intended for pain management without the psychoactive effects of THC.
- MMS019, a high-density molecular masking spray for airborne viruses, aiming to reduce transmission and infection rates.
Virpax Pharmaceuticals executive team
- Mr. Jatinder DhaliwalCEO & Chairman
- Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.Chief Scientific Officer